Masimo Corp. (NASDAQ:MASI) CEO Joe E. Kiani sold 20,381 shares of the stock in a transaction on Friday, November 18th. The shares were sold at an average price of $62.02, for a total value of $1,264,029.62. Following the completion of the transaction, the chief executive officer now owns 119,241 shares of the company’s stock, valued at approximately $7,395,326.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Masimo Corp. (NASDAQ:MASI) opened at 61.78 on Wednesday. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of 29.83 and a beta of 0.98. The firm’s 50-day moving average price is $59.15 and its 200-day moving average price is $55.37. Masimo Corp. has a 12 month low of $33.03 and a 12 month high of $62.25.

Masimo Corp. (NASDAQ:MASI) last released its earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.10. The company earned $167.60 million during the quarter, compared to the consensus estimate of $165.51 million. Masimo Corp. had a return on equity of 29.42% and a net margin of 16.31%. The firm’s quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.36 earnings per share. On average, equities analysts anticipate that Masimo Corp. will post $2.14 earnings per share for the current year.

Insider Buying and Selling by Quarter for Masimo Corp. (NASDAQ:MASI)

A number of equities analysts recently weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $75.00 price target on shares of Masimo Corp. in a research report on Monday, November 14th. Zacks Investment Research lowered Masimo Corp. from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Piper Jaffray Cos. restated an “overweight” rating and set a $55.00 price objective (up from $52.00) on shares of Masimo Corp. in a research report on Friday, August 5th. Finally, BTIG Research restated a “hold” rating on shares of Masimo Corp. in a research report on Friday, August 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $55.00.

Several large investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. increased its stake in Masimo Corp. by 42.8% in the third quarter. D.A. Davidson & CO. now owns 1,713 shares of the company’s stock worth $101,000 after buying an additional 513 shares during the last quarter. Victory Capital Management Inc. increased its stake in Masimo Corp. by 76.9% in the second quarter. Victory Capital Management Inc. now owns 2,148 shares of the company’s stock worth $113,000 after buying an additional 934 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in Masimo Corp. during the second quarter worth $116,000. Acrospire Investment Management LLC increased its stake in Masimo Corp. by 22.2% in the third quarter. Acrospire Investment Management LLC now owns 2,200 shares of the company’s stock worth $131,000 after buying an additional 400 shares during the last quarter. Finally, First Quadrant L P CA purchased a new stake in Masimo Corp. during the third quarter worth $138,000. Institutional investors own 82.77% of the company’s stock.

WARNING: “Joe E. Kiani Sells 20,381 Shares of Masimo Corp. (MASI) Stock” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2016/11/23/joe-e-kiani-sells-20381-shares-of-masimo-corp-masi-stock.html.

Masimo Corp. Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.

5 Day Chart for NASDAQ:MASI

Receive News & Stock Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related stocks with our FREE daily email newsletter.